Termites mitigate the effects of drought in tropical rainforest

Acknowledgments: This work was supported by the South East Asia Rainforest Research Partnership (SEARRP) with permission from the Maliau Basin Management Committee. We thank G. Reynolds, U. Jami, and L. Kruitbos for coordinating fieldwork; S. Both and U. Kritzler for help in establishing the experimental plots; R. Walsh for providing rainfall data; and A. Zanne and A. Cheesman for discussions on experimental design. We thank J. Nash from Bayer Southeast Asia Pte-Ltd, Singapore, for donating Premise 200SC and Agenda 10SC. We thank J. Rees, A. Tagliabue, M. Begon, R. Williams, W. Cheng, C. Dahlsjö, R. Kitching, and J. Barlow for comments on the manuscript. Finally, we thank all our field assistants: R. Binti Manber, A. Jupri, F. John, Y. Binti Suffian, E. Bin Esing, D. Bin Paul, Z. Bin Angau, A. Allbanah Bin Anchun, N. Angau, D. Ku Shamirah Binti Pg Bakar, E. Binti Nahun, R. Rusili, A. Bin Rantau, R. Bin Sahamin, A. Mastor, M. Adzim Bin Rahili, M. Azuan, H. Nasir, and N. Fazzli. Funding: This publication is a contribution from the UK NERC-funded Biodiversity And Land-use Impacts on Tropical Ecosystem Function (BALI) consortium (NERC grant NE/L000016/1). Author contributions: C.L.P., H.M.G., L.A.A., P.E., and T.A.E. conceived and designed the experiment; C.L.P., P.E., and T.A.E. established the experimental plots; H.M.G., L.A.A., and P.E. collected the data; H.M.G., L.A.A., P.E., and R.K.D. analyzed the data; C.S.V., F.H., and H.S.T. carried out laboratory analysis; H.M.G. and L.A.A. led the writing of the manuscript with significant input from C.L.P., P.E., R.K.D., and Y.A.T. Competing interests: None declared. Data and materials availability: Data have been deposited in the NERC Environmental Information Data Centre (37).Peer reviewedPostprin

Co-producing a Research Agenda for Sustainable Palm Oil

The rise of palm oil as the world’s most consumed vegetable oil has coincided with exponential growth in palm oil research activity. Bibliometric analysis of research outputs reveals a distinct imbalance in the type of research being undertaken, notably a disproportionate focus on biofuel and engineering topics. Recognizing the expansion of oil palm agriculture across the tropics and the increasing awareness of environmental, social, and economic impacts, we seek to reorientate the existing research agenda toward one that addresses the most fundamental and urgent questions defined by the palm oil stakeholder community. Following consultation with 659 stakeholders from 38 countries, including palm oil growers, government agencies, non-governmental organizations, and researchers, the highest priority research questions were identified within 13 themes. The resulting 279 questions, including 26 ranked as top priority, reveal a diversity of environmental and social research challenges facing the industry, ranging from the ecological and ecosystem impacts of production, to the livelihoods of plantation workers and smallholder communities. Analysis of the knowledge type produced from these questions underscores a clear need for fundamental science programmes, and studies that involve the consultation of non-academic stakeholders to develop “transformative” solutions to the oil palm sector. Stakeholders were most aligned in their choice of priority questions across the themes of policy and certification related themes, and differed the most in environmental feedback, technology and smallholder related themes. Our recommendations include improved regional academic leadership and coordination, greater engagement with private and public stakeholders in Africa, and Central and South America, and enhanced collaborative efforts with researchers in the major consuming countries of India and China.The online survey and focus groups were funded by the Geran Kursi Endowmen MPOB-UKM Malaysia, and the Royal Geographical Society UK. The residential workshop was supported from by British Council and Academy Science Malaysia via the UK Newton Ungku-Omar Fund. ZD, JB, and MS are supported by the UK Natural Environment Research Council (NE/K016407/1; http://lombok.nerc-hmtf.info/)

Serelaxin as a potential treatment for renal dysfunction in cirrhosis: Preclinical evaluation and results of a randomized phase 2 trial

<div><p>Background</p><p>Chronic liver scarring from any cause leads to cirrhosis, portal hypertension, and a progressive decline in renal blood flow and renal function. Extreme renal vasoconstriction characterizes hepatorenal syndrome, a functional and potentially reversible form of acute kidney injury in patients with advanced cirrhosis, but current therapy with systemic vasoconstrictors is ineffective in a substantial proportion of patients and is limited by ischemic adverse events. Serelaxin (recombinant human relaxin-2) is a peptide molecule with anti-fibrotic and vasoprotective properties that binds to relaxin family peptide receptor-1 (RXFP1) and has been shown to increase renal perfusion in healthy human volunteers. We hypothesized that serelaxin could ameliorate renal vasoconstriction and renal dysfunction in patients with cirrhosis and portal hypertension.</p><p>Methods and findings</p><p>To establish preclinical proof of concept, we developed two independent rat models of cirrhosis that were characterized by progressive reduction in renal blood flow and glomerular filtration rate and showed evidence of renal endothelial dysfunction. We then set out to further explore and validate our hypothesis in a phase 2 randomized open-label parallel-group study in male and female patients with alcohol-related cirrhosis and portal hypertension. Forty patients were randomized 1:1 to treatment with serelaxin intravenous (i.v.) infusion (for 60 min at 80 μg/kg/d and then 60 min at 30 μg/kg/d) or terlipressin (single 2-mg i.v. bolus), and the regional hemodynamic effects were quantified by phase contrast magnetic resonance angiography at baseline and after 120 min. The primary endpoint was the change from baseline in total renal artery blood flow.</p><p>Therapeutic targeting of renal vasoconstriction with serelaxin in the rat models increased kidney perfusion, oxygenation, and function through reduction in renal vascular resistance, reversal of endothelial dysfunction, and increased activation of the AKT/eNOS/NO signaling pathway in the kidney. In the randomized clinical study, infusion of serelaxin for 120 min increased total renal arterial blood flow by 65% (95% CI 40%, 95%; <i>p <</i> 0.001) from baseline. Administration of serelaxin was safe and well tolerated, with no detrimental effect on systemic blood pressure or hepatic perfusion. The clinical study’s main limitations were the relatively small sample size and stable, well-compensated population.</p><p>Conclusions</p><p>Our mechanistic findings in rat models and exploratory study in human cirrhosis suggest the therapeutic potential of selective renal vasodilation using serelaxin as a new treatment for renal dysfunction in cirrhosis, although further validation in patients with more advanced cirrhosis and renal dysfunction is required.</p><p>Trial registration</p><p>ClinicalTrials.gov <a href="https://clinicaltrials.gov/ct2/show/NCT01640964" target="_blank">NCT01640964</a></p></div